Abu Dhabi carries out first robotic surgery to remove appendiceal tumour
A 48-year-old patient with a rare appendiceal tumour has become the first in Abu Dhabi to undergo a robotic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC).
Dr. Yasir Akmal, Staff Physician in the Digestive Disease Institute, led a multi-disciplinary team at Cleveland Clinic Abu Dhabi to perform the complex procedure.
It involved the removal of multiple internal organs to prevent the spread of the tumour in the patient's abdomen, and the administration of the HIPEC treatment where heated chemotherapy (42 degrees Celsius) is circulated within the abdominal cavity to eliminate any residual cancer cells.
The patient, who initially presented symptoms resembling appendicitis, was undergoing a procedure to remove the organ when the surgeons discovered gelatinous deposits (jelly-like substance) in the abdominal cavity.
A subsequent pathology report confirmed the presence of a rare low-grade mucinous neoplasm, a tumour that, if untreated, could spread throughout the abdomen and result in a condition known as pseudomyxoma peritonei or 'jelly belly".
Dr. Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi, highlighted that the "minimally invasive techniques... (helps) improve outcomes and enhance quality of life".
According to the official stats, appendiceal tumours account for less than 1 per cent of malignancies worldwide and are found in approximately 1.4 per cent of patients who undergo an appendectomy.
Highlighting both the preventive and curative nature of the surgery, Dr. Akmal said that the patient's condition was diagnosed at an advanced but treatable stage, and thanks to the timely intervention of the multidisciplinary team, supported by specialised AI-driven diagnostic tools, the team was able to navigate the process of eliminating the cancer cells in her body with precision.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The National
4 days ago
- The National
Abu Dhabi's dedicated cancer centre treats 25,000 patients in first two years
A dedicated Abu Dhabi cancer centre has delivered crucial treatment to more than 25,000 patients since opening to the public two years ago under a vision to transform health care in the Emirates. Health leaders at the Fatima bint Mubarak Centre, based at Cleveland Clinic Abu Dhabi, have told of their mission to "lead the future of oncology" from the UAE capital. Patients at the centre, which is modelled on Cleveland Clinic's Taussig Cancer Centre in the US, receive personalised care for in all forms of cancer from individual teams with expertise, comprises oncologists, surgeons, radiologists, radiation therapists, nurses and rehabilitation specialists. 'Gone are the days when a patient needs to go from place to place, everything they need is here,' said Dr Stephen Grobmyer, head of the Fatima bint Mubarak Cancer Centre, which opened in March 2023. Don't delay in seeking support But doctors say the public must also play their part to win the fight against cancer, by ensuring they do not delay in going for check-ups. 'We need people to understand that a delay in diagnosis is often a missed opportunity,' said Dr Fady Geara, chairman of radiation oncology. 'We are seeing patients who wait weeks or months before seeking help and, by the time they arrive, their window for a cure may already be closing.' The critical need for early intervention was highlighted in recent research, which indicated a 60 per cent rise in newly diagnosed cases between 2019 an 2023. The series paper, titled Cancer Control in the United Arab Emirates, co-written by leading UAE-based oncologists and global experts, called for an urgent and comprehensive national strategy to address rising cases, inequities in care and preventive services not being used enough. 'We're urging people to get screened, especially those with family histories or known risk factors,' Dr Geara said. 'The hardship of travelling abroad for care is no longer necessary. World-class treatment is available right here.' World-class care Dr Usman Ahmad, chairman of thoracic surgery, who leads the institute's robotic and minimally invasive surgery programme, agreed patients no longer having to travel abroad for treatment was a huge advantage. 'Robotic surgery allows us to operate through small keyhole incisions with exceptional precision and safety," he added. "The result is less pain, fewer complications and much faster recovery times.' The programme includes surgery for lung, oesophageal, stomach, prostate, kidney, bladder and gynaecological cancer. 'Our patients start walking the same day or the next, go home in a few days and recover fast enough to begin follow-up therapies such as chemotherapy or immunotherapy without delay,' said Dr Ahmad. Radiation oncology has also undergone major advancements under Dr Geara. 'We've brought in the most advanced technologies, including adaptive radiation therapy, brachytherapy and radio surgery,' he said. 'These methods reduce treatment sessions while improving cure rates and they're all now available right here in the UAE.' Brachytherapy, which involves using radiation directly on or near a tumour, is rarely found even in some major hospitals abroad. It is now carried out daily at the centre. Dr Geara said the institute had also begun work on a dedicated heavy ion therapy complex, a carbon-ion therapy considered among the most advanced in the world, capable of targeting tumours that cannot be treated through conventional means. Construction of the heavy ion centre is expected to take two to three years. Cleveland Clinic Abu Dhabi's cancer programme extends far beyond treatment. Under the leadership of Dr Fawad Khan, the longevity medicine section has introduced a pioneering preventive care programme for cancer survivors and those at high genetic risk of developing the disease. This includes comprehensive genetic screening, counselling and prevention strategies, from enhanced screening and medication to preventive surgery. The longevity medicine team comprises lifestyle physicians, physical therapists, genetic counsellors, naturopaths and psychologists. A major element of the programme is its use of precision genomics. 'We're conducting germ line, somatic and pharmacogenomic testing to guide treatment, prevent cancer and minimise side effects,' said Dr Khan. They collaborate closely with the Emirati Genome Programme and M42, allowing access to data crucial to bolstering care and mitigating health risks. One study now under way involves the use of polygenic risk scores to better identify breast cancer risks in Emirati women. 'This research has largely focused on western populations,' Dr Khan said. 'By focusing on Arab populations, we can greatly improve regional outcomes and design tailored prevention programmes.' Clinical trials are another growing sector. 'Trials are how new treatments come into the world,' said Dr Grobmyer. 'It's no longer enough to assume treatments tested abroad will work here. We need to prove they do with local data and regional representation.' A newly launched programme uses wearable BioButton sensors to track vital signs in real time once a patient leaves the hospital. Nurses can detect early signs of infection, dehydration, or other complications and intervene before symptoms worsen. 'The technology allows us to call patients before they call us,' said Dr Grobmyer. 'In many cases, we've been able to prevent hospital readmissions entirely.' He said the programme is already being used in chemotherapy patients and is expected to expand across surgical units. Long-term strategy The institute is also preparing the next generation of physicians. Next year, it will launch a four-year residency in oncology, accredited by the UAE board. Preference will be given to Emirati candidates, with the goal of building a sustainable domestic workforce in cancer care. 'Our long-term goal is not just to be takers of global excellence but contributors to it,' said Dr Grobmyer. 'Through clinical research, genomics, AI and training, we want to lead the future of oncology here in Abu Dhabi and around the world.'
Khaleej Times
4 days ago
- Khaleej Times
Inside UAE's most advanced cancer centre: Wearables, robotic surgery, carbon-ion therapy
From real-time patient monitoring and robotic surgery to genomic screening and heavy-ion therapy, Cleveland Clinic Abu Dhabi's Fatima bint Mubarak Center is progressing how cancer is diagnosed, treated, and prevented in the UAE. Marking its second anniversary, the centre's leadership presented a series of updates that reflect the growing scale and sophistication of the country's cancer care infrastructure. "We've treated over 27,000 cancer patients since inception," said Dr Stephen Grobmyer, Chief of the Cancer Institute. "But what's more exciting is where we're going." Wearables and cooling devices Among the most immediate changes affecting patients today is the roll-out of the BioButton, a medical-grade wearable that remotely tracks a patient's vital signs after chemotherapy or surgery. "We're putting it on almost all patients who start on chemotherapy," Dr Grobmyer confirmed, adding that it allows clinicians to identify signs of deterioration early and proactively intervene. "We can detect early warning signs like increased temperature or heart rate before the patient even notices. One of our patients, for example, was starting to experience complications like nausea and vomiting. We contacted them before it escalated, brought them in for fluids, and they were able to return home without hospital admission." The centre is also investing in supportive technologies to preserve the quality of life during treatment. Cooling caps, used to reduce chemotherapy-related hair loss, have already shown tangible results. "I had a patient last week who finished chemotherapy and still had almost all of her hair. She was very happy about that," said Dr Grobmyer. For patients facing neuropathy, a side effect of some cancer medications, cooling gloves are being used to reduce nerve damage in hands and feet. Robotic surgery = smaller cuts, faster recovery Dr Usman Ahmad, division chair of Thoracic Surgery, Heart, Vascular and Thoracic Institute, explained how Cleveland Clinic Abu Dhabi has made robotic and minimally invasive surgery the new norm for cancer patients across specialities. "There is no surgical treatment for which the patients have to leave the UAE now," he said. He emphasised the dramatic improvement in recovery times through robotic surgery. "Instead of big incisions, we operate through keyholes. Patients start walking the same day or the next, go home in a few days, and can start further treatment like chemotherapy or immunotherapy within a week or two." He described the shift from older surgical methods in vivid terms: "The robotic technology is so advanced that the instruments act like my hands inside the patient's body, without me having to put my hands inside. Traditional thoracic surgery might require an incision this big," he said, gesturing from his heart to the abdomen area. "Now, we do the entire operation through incisions the size of a fingertip." Dr Ahmad noted that nearly all types of cancer surgeries, including for lung, stomach, oesophagus, kidney, prostate, and ovarian cancers, are now performed robotically. "We don't compromise on safety or quality. These are the same standards you'd find in the US or Europe." AI, adaptive radiation and heavy ion therapy Radiation oncology has also seen a leap forward, with Cleveland Clinic Abu Dhabi now offering AI-powered adaptive radiation and brachytherapy, internal radiation delivered directly to the tumour. "Adaptive radiation is among the most advanced in the world," said Dr Fady Geara, Division Chair of Radiation Oncology. "We adjust the radiation in real-time during treatment to follow the tumour's exact position and spare healthy tissue." He added that this is especially useful for abdominal and pelvic cancers, where organs shift frequently. The centre's brachytherapy programme is now operating daily and, according to Dr Geara, is often "not even available in many US centres." As previously announced, the facility is preparing to launch the region's first carbon-ion therapy centre - a treatment for tumours resistant to traditional methods. "We're building a new facility to house the synchrotron accelerator," said Dr Geara. "We aim to treat our first patient in two to three years, or possibly sooner." Genomics, prevention, and regional leadership A polygenic risk score (PRS) study to predict breast cancer in patients without known genetic mutations is also underway. "Most global data is from Western populations," said Dr Fawad Khan, Staff Physician for Longevity Medicine. "We're now validating this in Emiratis, which will also benefit the wider Arab population." The hospital's longevity and high-risk prevention programmes already serve hundreds of patients, both survivors and those with elevated risk, including international patients from Saudi Arabia and Qatar. "This is not a branch of Cleveland Clinic," Dr. Grobmyer emphasised. "We are Cleveland Clinic. Our tumour boards include our colleagues in Ohio, and our goal is not just to take from the system but to contribute new knowledge back." Training the next generation As part of that long-term vision, the centre has received approval to launch a four-year oncology residency programme starting in 2026. "Our preference is to train locals - Emirati doctors, but we also bring in candidates from the wider region when needed," said Dr Grobmyer. He noted that the programme, accredited through the UAE's board system, is designed to match the standards of top US fellowships. "It's a long journey," he added, describing the structure as a progression from internal medicine training to subspecialty practice in solid tumour oncology and malignant haematology. Once trainees complete the full programme and pass board exams, "they will be independently able to manage the full spectrum of diseases," he explained, Dr Ahmad stressed how early detection saves lives, and no one in the UAE needs to leave the country for treatment as they could receive timely, high-quality, sufficient treatment in the capital. "While our technology is world-class, it's only useful if people get to us in time," he concluded.
Al Etihad
5 days ago
- Al Etihad
Cleveland Clinic Abu Dhabi delivers first infusion therapy for Parkinson's in region
17 June 2025 11:31 ABU DHABI (WAM) Cleveland Clinic Abu Dhabi, part of the M42 group, has successfully introduced continuous infusion therapy, a cutting-edge therapeutic treatment for advanced Parkinson's disease, making it the first hospital in the GCC region to offer this innovative therapy offers a groundbreaking alternative for patients who are not candidates for DBS or prefer a non-invasive all patients in the advanced stages of Parkinson's are eligible for it. It delivers a continuous subcutaneous infusion of levodopa-carbidopa—the gold-standard medication for Parkinson's—through a compact pump connected to the skin. Unlike oral medications, which can lead to fluctuating absorption and inconsistent symptom control, this approach provides a steady, around-the-clock infusion, ensuring more stable symptom post-treatment follow-ups are significantly reduced to once every six months, compared to the frequent monitoring required after DBS surgery, making it a more convenient long-term option for by an exceptional team of Parkinson's disease specialists providing 24/7 care, alongside a dedicated rehabilitation team and other medical professionals, Cleveland Clinic Abu Dhabi ensures patients receive the highest level of comprehensive, patient-centred on bringing advanced and tailored treatment solutions to the region, Dr. Georges-Pascal Haber, the CEO of Cleveland Clinic Abu Dhabi, said, 'The introduction of continuous therapy in the UAE and GCC represents a critical advancement in how we approach patient care and outcomes in the region. As neurodegenerative diseases become more prevalent, patients are increasingly in need of personalised, innovative solutions.'Highlighting the impact of the therapy, Dr. Shivam Om Mittal, Staff Physician, Neurological Institute at Cleveland Clinic Abu Dhabi, who led the treatment, said, 'We are proud to be the first in the region to offer this groundbreaking therapy so soon after its global introduction. At Cleveland Clinic Abu Dhabi, we provide a full spectrum of advanced Parkinson's treatments—including oral medication, deep brain stimulation (DBS), and now this treatment, ensuring each patient receives a personalised care plan. Additionally, our exceptional team of Parkinson's disease specialists, supported by a dedicated rehabilitation team and other medical professionals, ensures 24/7 care and comprehensive support for our patients at every stage of their journey.'The infusion system functions much like an insulin pump, with a compact, phone-sized device connected to a fine tube placed on the skin. It delivers a continuous infusion of Parkinson's medication throughout the day and night, maintaining stable drug levels and significantly reducing motor fluctuations and innovation is transforming how we manage advanced Parkinson's disease, offering patients greater stability, independence, and an improved quality of life. Additionally, its straightforward design makes it easy to implement, providing a seamless transition for both patients and Parkinson's disease being the fastest-growing neurodegenerative condition worldwide—expected to double by 2040—the need for innovative, effective treatments has never been more urgent. Currently, 1% of individuals over 60 years old are affected globally, with an increasing number of young-onset cases under 50 being its introduction in 2019 by Cleveland Clinic Abu Dhabi, deep brain stimulation (DBS) surgery has been the leading advanced treatment for Parkinson's in the UAE. The hospital has now successfully performed over 100 Clinic Abu Dhabi, through the pioneering introduction of continuous infusion therapy in the GCC, is leading the charge in neurological marks a significant step forward in the UAE's ambition to become a global hub for medical innovation. With its multidisciplinary approach to patient care, where neurology, surgery, rehabilitation, and other specialities collaborate seamlessly, it continues to set new standards in advancing treatment options that transform patient outcomes and improve lives across the region.
